Analytical Data
-
Gene name
TNFSF13B
- Application
-
Alternative Names
TNFSF13B；BCM；BCMA；Tumor necrosis factor receptor superfamily member 17
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y275
-
Expression Region
134-285aa
-
AA Sequence
AVQGPEETVTQDCLQLIADSETPTIQKGSYTFVPWLLSFKRGSALEEKENKILVKETGYFFIYGQVLYTDKTYAMGHLIQRKKVHVFGDELSLVTLFRCIQNMPETLPNNSCYSAGIAKLEEGDELQLAIPRENAQISLDGDVTFFGALKLL
-
Molecular Weight
46.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TNFSF13B, also known as B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) superfamily that plays a crucial role in the regulation of B cell survival, differentiation, and maturation. Its importance in immune responses has led to significant interest in understanding its biological functions and mechanisms of action. Dysregulation of TNFSF13B has been implicated in various autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis, making it a potential therapeutic target. Research on recombinant TNFSF13B protein aims to elucidate its structural and functional properties, assess its role in B cell dynamics, and explore its potential applications in disease treatment. Studies have shown that manipulating TNFSF13B levels can influence the proliferation of B cells and the production of immunoglobulins, highlighting its pivotal role in adaptive immunity. Additionally, recombinant forms of TNFSF13B are being investigated for their potential in developing new therapies for immune-related conditions, as well as in enhancing vaccine responses. Understanding the detailed interactions of TNFSF13B with its receptors and other signaling pathways is essential for designing effective interventions that can modulate immune responses in both autoimmune disorders and clinical settings. Thus, continued research on TNFSF13B recombinant protein holds promise for advancing our knowledge of immune regulation and improving therapeutic strategies in immunology.
